Answers are grounded in this paper and cite their sources.
Objective:The global severe acute respiratory syndrome-coronavirus-2 pandemic, which emerged in 2019, has resulted in severe complications in approximately 5% of infected individuals, leading to mortality due to respiratory failure, shock, or multiple organ dysfunction.Mortality is primarily attributed to excessive hyperinflammatory response-induced alveolar damage, which subsequently progresses to severe acute respiratory distress syndrome.Tocilizumab, a monoclonal antibody targeting the interleukin-6 receptor, has been utilized in the management of cytokine release syndrome (CRS) and is hypothesized to mitigate alveolar hyperinflammation, thereby reducing disease severity.Method: This retrospective study analyzed 76 patients diagnosed with coronavirus disease-2019 (COVID-19) pneumonia and developing CRS in the intensive care unit.The patients were divided into two groups: 39 patients who received tocilizumab (Group T) and 37 patients who did not receive tocilizumab (Group C).The primary objective of the study was to assess the effect of tocilizumab on the PaO 2 /FiO 2 ratio in critically ill COVID-19 pneumonia patients requiring mechanical ventilatory support.The secondary objective was to evaluate changes in inflammatory and Ama: 2019 ylnda tm dnyada ortaya kan iddetli akut solunum yolu sendromu-koronavirs-2'ye bal pandemi sonras enfekte bireylerin %5'inde solunum yetmezlii, ok veya multiorgan yetmezliine bal mortalite gelitii bilinmektedir.Mortalite, ounlukla ar hiperenflamatuvar yanta bal alveoler hasar ve ardndan gelien ciddi akut solunum sknts sendromu tablosuna bal olarak gelimektedir.Tocilizumab sitokin salnm sendromunda (CRS) kullanlan bir monoklonal antikordur.Alveoler hiperenflamasyonu azaltarak hastaln iddetini azaltt dnlmektedir.Yntem: Bu almada, youn bakm nitesinde 18-80 ya aras koronavirs hastal-2019 (COVID-19) pnmonisi tans alm hastalar retrospektif olarak incelendi.CRS gelien toplam 76 hasta almaya dahil edildi; 39 hasta tocilizumab uygulanan Grup T, 37 hasta ise tocilizumabn temin edilemedii dnemin kaytlarndan elde edilen kontrol grubu (Grup C) olmak zere iki gruba ayrld.Bu almann primer amac youn bakmda mekanik ventilatr destei altnda takip edilen COVID-19 pnmonili, CRS gelien bireylerde interlkin-6 reseptr blokr tocilizumabn kullanmnn PaO 2 /FiO 2 oran zerine olan etkisini Evaluation of the Efficacy of Tocilizumab in Cytokine Release Syndrome in Patients with COVID-19 (SARS-CoV-2) Pneumonia Followed in the Intensive Care Unit Youn Bakm nitesinde Takip Edilen COVID-19 (SARS-CoV-2)
No takes yet. Share an insight, caveat, or question.
Şehirlioğlu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: